AWS Health Innovation Podcast AWS Startups

Explore how Us2.AI, Truvian Health, and Sparta Science leverage AI, cloud, and novel biological insights to revolutionize diagnostics and biomarker discovery, enabling accessible and precise care pathways.

Dive into the groundbreaking approaches of companies like VivoDyne, Seer, Ordaos, Insilico Medicine, and Alchemab, who are pushing boundaries in drug R&D through microfluidic bioengineering, proteome mapping, AI-driven drug design, and resilient antibody discovery.

Mendel enables life sciences to index patient journeys at scale and learn from them at the speed of real-time dialogues. The journey started in 2017 from a two-person office in Silicon Valley with commitment to building novel technology and not to be another “Boy Who Cried Wolf” AI company. To do that, we have invested 4 years and millions of dollars in R&D before launching our first model in 2020. Today, Mendel is the most-funded clinical NLP startup with a team of 100+ members, blue chip investors, and some of the world’s leading life sciences companies as customers.

Vivodyne, a biotech firm employing bottom-up self-assembly principles to grow complex tissues that better mimic human physiology, enabling the study of systemic effects like immune responses and linking multiple tissue systems.

Iktos is an innovative company specializing in the development of artificial intelligence solutions applied to chemical research and new drug design, enabling major productivity gains in upstream pharmaceutical R&D.

DeepLife uses machine learning to curate and annotate single-cell RNA-seq datasets, enabling downstream bioinformatics analysis and target identification.